Lv21
140 积分 2021-10-29 加入
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression
5小时前
待确认
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
1个月前
已完结
[China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2023)]
2个月前
已完结
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
2个月前
已完结
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
3个月前
已完结
[Clinical analysis of immunotherapy rechallenge in advanced gastric cancer]
4个月前
已完结
Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
4个月前
已关闭
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
5个月前
已完结
Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study
6个月前
已完结
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
7个月前
已完结
皖公网安备34019202002308
